CSL Limited
(ASX:CSL) has advised the US Food and Drug Administration will look into one of its treatments.
The biopharmaceutical products manufacturer says US drug regulators will review its treatment for haemophilia.
The review comes following a pivotal clinical trial which exhibited promising results.
Haemophilia is a congenital bleeding disorder where people can experience prolonged or spontaneous bleeding.
CSL reported a net profit of $843.9 million in the first half of 2015 financial year.
